Nilo Therapeutics’ Series A round was led by The Column Group, DCVC Bio, and Lux Capital. The preclinical startup is developing drugs targeting neural circuits that control systemic inflammation.
The post Startup Nilo Launches With $101M for Autoimmune Drugs That Target ‘Brain-Body Circuits’ appeared first on MedCity News.
